Close Menu

clopidogrel

The community is poised to be the primary channel for stakeholders to communicate PGx concerns with FDA, but it is unclear if all stakeholders will participate.

The TAILOR-PCI trial did not meet its primary endpoint but did find that genetic testing led to a reduction in adverse events, though not as much as expected.

The firm can now tell customers if their genotypes may impact their response to clopidogrel and citalopram without the need for confirmatory testing.

The Ottawa-based molecular diagnostics maker also plans to enter applied markets in the near term, and ultimately point-of-care infectious disease testing.

The latest analysis of CYP2C19 genotyping to guide antiplatelet therapy tries to address cost questions from the vantage of a payor or large healthcare system.

Originally published Oct. 31.
NEW YORK (GenomeWeb) – Spartan Bioscience is gearing up to commercialize its CYP2C19 test in Canada in the point-of-care setting, a previously untapped market for the company.

Can drugmakers be held liable for failing to aggressively warn consumers that patients with certain genetic markers will not respond or will have limited response to their drugs beyond just mentioning this information in drug labeling?

A study led by researchers from Brigham and Women's Hospital on the effect of CYP2C19 testing on physicians' prescribing patterns has found that when doctors received patient test results for genetic markers associated with clopidogrel response through a pharmacy-benefit manager-

This article has been updated to note that PDI is moving away from the contract sales business with drug companies. Originally published Oct. 22.

Having published research last year identifying a novel haplotype that may alter the interpretation of CYP2C19 genotyping, clinical researchers from the Icahn School of Medicine at Mount Sinai in New York have now published a paper describing an allele-specific PCR assay to detec

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.